TITLE: GENOMIC ALTERATIONS IN THE TUMOR AND CIRCULATION OF PANCREATIC CANCER PATIENTS
CASE NUMBER: C13433
UNMET NEED
Several genetic alterations have been identified in pancreatic cancers, including those in certain tumor suppressor genes and in oncogene. Although the discoveries of these genes and their pathways have provided important insights into the natural history of pancreatic cancer and have spurred efforts to develop improved diagnostic and therapeutic agents, few genetic alterations discovered to date in pancreatic cancer have been used to directly affect clinical care. Therefore, identification of genetic alterations that may be related to patient outcome and other clinical characteristics are needed.
PROBLEM SOLVED
The inventors were able to highlight information that may be obtained through the integration of large-scale genomic and clinical analyses in pancreatic cancer. Through integrated genomic analyses they identified chromatin-regulating genes as markers of improved prognosis and highlighted clinically actionable alterations in genes not typically evaluated during clinical care of pancreatic cancer patients. Also, circulating tumor DNA (ctDNA) in the circulation of pancreatic cancer patients may provide a marker of early detection of sub-clinical, residual or recurrent disease. These analyses suggest future efforts to evaluate more intensive therapies for patients without the chromatin-regulating genes alterations or with detectable ctDNA after surgical resection, as well as interventional clinical trials based on actionable alterations observed in pancreatic cancer patients.
STAGE OF DEVELOPMENT
-The invention is at the preclinical stage of development. The investigators have data from next generation sequencing of the entire exomes of matched tumor-normal specimens and targeted sequencing of patient tumors, which identify sequence changes, including single base and small insertion or deletion mutations, as well as copy number alterations in >20,000 genes in the whole-exome analyses and in 116 specific genes in the targeted analyses. These data were analyzed for survival characteristics as well as evaluated for the utility of using somatic mutations in circulating tumor DNA (ctDNA) to identify patients likely to recur after surgical intervention.
DISEASE INDICATION
Pancreatic Cancer
ASSOCIATED PUBLICATIONS
- PMC4634573 -
TECHNOLOGY CLASSIFICATION
Primary Category: Clinical Diagnostics/In Vitro Diagnostics
Primary Subcategory: Therapeutics
ASSOCIATED REPORTS OF INVENTION (ROIs) AND INTELLECTUAL PROPERTY (IP) FILING NUMBERS
ROI # TITLE
C13433 Genomic Alterations in the Tumor and Circulation of Pancreatic Cancer Patients
STATUS PRIORITY DATE IP FILING NUMBERS
Application filed 2/20/2015 US 62/118,604
